Arpeggio Bio
John started his career at Bristol-Myers Squibb as a group leader of discovery chemistry. Currently, John advises early-stage companies on their medicinal chemistry design and interfaces with CROs to drive fast and accurate preclinical development.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Arpeggio Bio
Arpeggio Bio's technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment.